Browsing Tag
evorpacept
4 posts
How ALX Oncology Holdings Inc is repositioning its clinical strategy to achieve pivotal trial readiness by end-2026
ALX Oncology outlines its 2026 pivotal trial roadmap as ASPEN-09 expands and $150m funding extends runway. Read what changes next.
Why predictive biomarkers may determine ALX Oncology’s competitive viability in HER2-positive breast cancer
Find out why CD47 biomarkers could determine ALX Oncology’s ability to compete in HER2-positive breast cancer and what risks remain for evorpacept.
ALX Oncology gets EC’s orphan drug status for evorpacept in gastric cancer
ALX Oncology Holdings, an Australian immuno-oncology company focusing on CD47 checkpoint pathway blocking therapies, declared a significant milestone…
ALX Oncology’s evorpacept gets FDA ODD for gastric cancer and gastroesophageal junction cancer
ALX Oncology said that its CD47 blocker evorpacept has secured orphan drug designation (ODD) from the US Food…